The authors of another paper documented the administration of HBOT as adjuvant therapy for acute macular neuroretinopathy in systemic lupus erythematosus in conjunction with immunosuppression in two patients [11].These benefits differ noticeably from All those claimed by Maalej et al. [24], who demonstrated a reduction in central macular thickness